Asunto(s)
Virus de la Influenza A/inmunología , Virus de la Influenza B/inmunología , Vacunas contra la Influenza/inmunología , Estaciones del Año , Adolescente , Adulto , Anticuerpos Antivirales/sangre , Humanos , Vacunas contra la Influenza/administración & dosificación , Vacunas contra la Influenza/efectos adversos , Gripe Humana/prevención & control , Persona de Mediana Edad , Rumanía , Vacunas Combinadas/administración & dosificación , Vacunas Combinadas/efectos adversos , Vacunas Combinadas/inmunología , Vacunas de Productos Inactivados/administración & dosificación , Vacunas de Productos Inactivados/efectos adversos , Vacunas de Productos Inactivados/inmunologíaRESUMEN
From 1982 to 1988 a serological survey was performed on 573 subjects aged 3-80 years in order to evaluate the polio immunity level of the population. The presence of neutralizing antibodies was tested using the types 1, 2 and 3 Sabin vaccine strains as well as a wild strain of poliovirus type 1 isolated in France in 1978. According to their birth date, the subjects were assigned to 4 groups. The differences between the groups consisted in the different vaccination history of the subjects as well as in their different opportunities of having been in contact with the past epidemics of poliomyelitis. The results obtained indicate a satisfactory polio immunity level in all the 4 groups: seropositives, 96.7%-98.9% for type 2, 91.8%-98.2% for type 1 (Sabin vaccine strain), 89.3%-96.6% for type 3 and 84.2%-96.4% for type 1 wild strain. The highest immunity levels were found in group D (children with recorded history of complete polio vaccination) and in group A (unvaccinated people but contemporary with the past polio epidemics). A special comment is made with respect to 14 subjects showing satisfactory antibody titres for all the three types of Sabin-vaccine strains but who have proved to be seronegative (less than 4) for the wild type 1 poliovirus strain.
Asunto(s)
Anticuerpos Antivirales/análisis , Poliomielitis/epidemiología , Poliovirus/inmunología , Factores de Edad , Formación de Anticuerpos , Humanos , Pruebas de Neutralización , Poliomielitis/inmunología , Vacuna Antipolio Oral/inmunología , RumaníaRESUMEN
From 1979 to 1985 a serological survey was carried out to evaluate the opportunity to start measles vaccination at the age of 9 months. The following aspects were investigated: the persistence of maternal measles antibodies in 188 infants aged 1-8 months: such antibodies could not be detected over 7 months of age; the antibody response to measles vaccination in 181 infants vaccinated at the age of 9-11 months versus 291 children vaccinated when aged more than 12 months: no significant differences were found between the two groups; the age-specific persistence of vaccine-induced hemagglutination-inhibiting antibodies during the 1-4 years following vaccination: no significant difference was found in terms of the children's age upon vaccination. The results lend support to the recommendation to consider 9 months as a satisfactory age to initiate measles immunization in Romania.
